Sanofi India (500674) Q1 2025 earnings summary

Executive summary

• Net sales grew 4% year-over-year for continuing business in Q1-2025, driven by product launches and operational efficiency.

• Operating profit increased 27% compared to Q1-2024, reflecting cost control and efficiency gains.

• The Consumer Healthcare business was demerged effective June 1, 2024; results are now reported as discontinued operations.

Financial highlights

• Revenue from operations for Q1-2025 was ₹5,359 million, up from ₹5,149 million in Q4-2024 and ₹5,108 million in Q1-2024.

• Profit before tax from continuing operations was ₹1,653 million, up from ₹1,045 million in Q1-2024.

• Net profit from continuing operations was ₹1,195 million, compared to ₹720 million in Q1-2024.

• Basic and diluted EPS from continuing operations was ₹51.89, up from ₹31.26 in Q1-2024.

Outlook and guidance

• Focus remains on expanding innovative product availability and further improving operating efficiencies in India.

• Continued execution of the 'India for India' strategy, emphasizing local market initiatives and innovation.